These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 15103748)

  • 1. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
    Grdisa M
    Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.
    Zent CS; Chen JB; Kurten RC; Kaushal GP; Lacy HM; Schichman SA
    Leuk Res; 2004 May; 28(5):495-507. PubMed ID: 15068903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
    Nückel H; Frey UH; Röth A; Dührsen U; Siffert W
    Eur J Pharmacol; 2005 May; 514(2-3):217-24. PubMed ID: 15910809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
    Smolewski P; Duechler M; Linke A; Cebula B; Grzybowska-Izydorczyk O; Shehata M; Robak T
    Leuk Res; 2006 Dec; 30(12):1521-9. PubMed ID: 16630656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells.
    Stanglmaier M; Reis S; Hallek M
    Ann Hematol; 2004 Oct; 83(10):634-45. PubMed ID: 15309525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
    Schriever F; Huhn D
    Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
    Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
    Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
    Heider U; Fleissner C; Zavrski I; Jakob C; Dietzel T; Eucker J; Ockenga J; Possinger K; Sezer O
    Eur J Haematol; 2004 Jan; 72(1):64-6. PubMed ID: 14962266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
    Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
    Robak P; Linke A; Cebula B; Robak T; Smolewski P
    Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
    Nabhan C; Gartenhaus RB; Tallman MS
    Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
    Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.